INTRODUCTION

Although many people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recover completely, others are left with long-lasting symptoms that persist for at least 4 weeks, a condition referred to by the National Institutes of Health (NIH) as post-acute sequelae of SARS-CoV-2 infection (PASC). The Centers for Disease Control and Prevention (CDC) defines post-COVID (coronavirus disease) conditions as the wide range of health consequences that are present for four or more weeks after infection with SARS-CoV-2, whereas the World Health Organization (WHO) refers to post-COVID condition as symptoms that persist...
beyond 12 weeks after an initial infection, last for at least 2 months, and cannot be explained by an alternative diagnosis. There are a number of terms found in the literature that describe this condition (e.g., long COVID, persisting symptoms post-COVID, post-acute COVID-19, long-haul COVID, and others), but for the purposes of this statement, the term PASC is used.

PASC can present with a non-specific constellation of signs and symptoms, some of which appear to be autonomic in nature. These include, but are not limited to, orthostatic intolerance, palpitations, tachycardia, syncope, orthostatic hypertension, labile blood pressures, dizziness, fatigue, and exercise intolerance. The most common autonomic diagnoses associated with PASC are orthostatic intolerance and postural orthostatic tachycardia syndrome (POTS), which often follow a viral infection. Other common features of PASC that may be related to autonomic dysfunction include cognitive impairment (often called “brain fog”), headache, insomnia, neuropathic pain, gastrointestinal and genitourinary dysfunction, and allergic symptoms suggestive of mast cell activation, such as pruritis, urticaria, flushing, angioedema, wheezing, food sensitivities, and others. Although the mechanisms of post-COVID autonomic dysfunction and PASC in general are being investigated, several possible etiologies have been proposed including autoimmunity, inflammation, persistent T-cell abnormalities, endothelial dysfunction, prothrombotic state, mast cell activation, small fiber neuropathy, and others. The mechanisms of post-COVID autonomic dysfunction and PASC in general are being investigated, several possible etiologies have been proposed including autoimmunity, inflammation, persistent T-cell abnormalities, endothelial dysfunction, prothrombotic state, mast cell activation, small fiber neuropathy, and others. Despite the prevalence of prolonged symptoms and emerging data on various manifestations and possible mechanisms, limited guidance exists regarding the assessment and treatment of the broad constellation of symptoms, including autonomic dysfunction, due to PASC. With this in mind, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Multi-Disciplinary PASC Collaborative (PASC Collaborative) was convened to address the urgent need for interim guidance in the care of patients with PASC. This document is part of a larger series addressing the most common manifestations of PASC, and specifically discusses the assessment and treatment of autonomic dysfunction. Fatigue, cognitive symptoms, respiratory sequelae, and cardiovascular complications of PASC are discussed elsewhere.

PASC consensus guidance statement methods

The PASC Collaborative was created, in part, to develop expert recommendations and guidance from established PASC centers with extensive experience in managing patients with PASC. The Collaborative is composed of 41 established post-COVID-19 or PASC centers, the first of which were established in April to June of 2020. The PASC Collaborative is following an iterative modified Delphi approach to achieve consensus on assessment and treatment recommendations for a series of consensus guidance statements focused on the most prominent PASC symptoms. The full description of this process has been published in detail previously.

At present, scientific evidence regarding effective assessment and treatment of PASC is limited, which prevents the creation of evidence-based clinical guidelines. These statements were developed by a diverse team of experts, with patient input, and integrate current experience and expertise with available evidence to provide tools to clinicians treating patients. There is an intentional focus on health equity as disparities in care and outcomes are critically important to address. Beyond offering recommendations for assessment and treatment based on experience with care of patients presenting with PASC symptoms, the hope is that a broadened understanding of current patient care practices will help identify areas of future research.

We acknowledge that the definition of PASC is evolving and that there are various factors that contribute to a diagnosis. In addition, PASC is broad and likely encompasses several different subtypes, some of which have overlapping clinical features. As such, the guidance statements developed by the PASC Collaborative are intended for broad audiences that could span primary care clinicians, physical medicine and rehabilitation physicians, and other specialists.

Considerations and caveats for implementation

This guidance statement is intended to reflect current practice in patient assessment, testing, and treatment, acknowledging the paucity of data on the diagnosis and treatment of PASC. In addition, we recognize the shortage of autonomic specialists in the United States, which limit access to specialized autonomic evaluation and testing for many patients. At the time of development of this guidance statement, the early literature focused on patients who were not vaccinated, and the incidence and trajectory of PASC in vaccinated patients with “breakthrough” cases (including current and emerging variants of the virus) is evolving. The PASC Collaborative considered these issues during the development process, and these guidance statements generally apply to individuals who develop PASC regardless of their vaccination status.

It is important to note that the recommendations provided in this guidance statement should not preclude clinical judgment and must be applied in the
Defining autonomic dysfunction

In this consensus statement, we use the term “autonomic dysfunction” to refer to any disturbance of the autonomic nervous system, including autonomic symptoms and common autonomic disorders, such as postural orthostatic tachycardia syndrome (POTS), neurocardiogenic syncope (NCS) which is also known as vasovagal syncope, orthostatic hypotension (OH), and inappropriate sinus tachycardia (IST). Orthostatic intolerance (OI) is used when objective tests do not confirm a diagnosis of one of the common autonomic disorders in a clinical setting of autonomic symptoms that are precipitated by an upright position and relieved by recumbency. The diagnostic criteria of POTS, NCS, OH, and IST are outlined in Table 1.\textsuperscript{1–22}

Based on PASC Collaborative discussion and patient feedback during the consensus process, we arrived at assessment and treatment guidance statements that may be utilized by health care practitioners when evaluating a patient with PASC-related autonomic dysfunction. We encourage health care practitioners to utilize this guidance because early evaluation, diagnosis, and management of autonomic dysfunction may ultimately improve functional impairment and reduce disability in patients with PASC.

AUTONOMIC DYSFUNCTION IN PATIENTS WITH PASC

The autonomic nervous system (ANS) consists of sympathetic, parasympathetic, and enteric divisions and is responsible for numerous physiologic functions, including cardiovascular control of heart rate and blood pressure, gastric motility and secretion, bladder function, respiration, temperature control, and distribution of blood flow to organs and tissue. The ANS mediates the “flight or fight” response to both external and internal stimuli in order to maintain homeostasis.\textsuperscript{23} There is evidence that the ANS is intimately involved in the process of inflammation, as the vagus nerve, which carries the parasympathetic nervous system output, is a major constituent of a neural reflex mechanism—the inflammatory reflex—that controls innate immune responses and inflammation during pathogen invasion and tissue injury.\textsuperscript{24} To this end, sympathetic overactivity may be associated with a pro-inflammatory state, while increased parasympathetic activity may have anti-inflammatory properties.\textsuperscript{25}

Autonomic symptoms and manifestations, including resting and postural tachycardia and orthostatic intolerance, have been frequently reported by patients after SARS CoV-2 infection.\textsuperscript{26,27} Other common symptoms include dizziness, lightheadedness, palpitations, presyncope, syncope, orthostatic intolerance, exercise intolerance, cognitive dysfunction, and fatigue. Gastrointestinal, respiratory, and genitourinary systems are reported as well (see Table 2).

New-onset autonomic disorders can develop after a variety of viral and bacterial infections, including influenza, Epstein–Barr virus, and \textit{Borrelia burgdorferi}.\textsuperscript{6,28} Case reports and series described POTS, OI, NCS, OH, IST, and autonomic neuropathy (AN) in patients following SARS-CoV-2 infection, with POTS being the most common autonomic disorder observed.\textsuperscript{29–31} OI is commonly diagnosed in patients with symptoms and

| TABLE 1 | Diagnostic criteria for common autonomic disorders. |
|---------|--------------------------------------------------|
| **Autonomic disorder** | **Diagnostic criteria** |
| POTS\textsuperscript{20} | 1. Sustained HR increase ≥30 bpm within 10 min for adults (≥40 bpm for adolescents 12–19 years of age) of standing or on TTT 2. Absence of OH 3. Symptoms of orthostatic intolerance for ≥6 months 4. Exclusion of other causes of postural tachycardia, such as dehydration, medication side effect, and other medical conditions |
| NCS\textsuperscript{20} | 1. Transient loss of consciousness typically preceded by prodromal symptoms and signs, such as pallor, diaphoresis, nausea, abdominal discomfort, yawning, sighing, and hyperventilation. That may occur up to 60 s prior to loss of consciousness. 2. A sudden fall in blood pressure, heart rate, and cerebral hypoperfusion on standing or on TTT |
| OH\textsuperscript{21} | Sustained drop in blood pressure ≥20/10 mm Hg within 3 min of standing or on TTT |
| IST\textsuperscript{22} | 1. Average sinus HR exceeding 90 bpm over 24 hours or HR while awake and at rest ≥100 bpm 2. Palpitations and other distressing symptoms associated with sinus tachycardia |

Abbreviations: bpm, beats per minute; HR, heart rate; IST, inappropriate sinus tachycardia; NCS, neurocardiogenic syncope; OH, orthostatic hypotension; POTS, postural orthostatic tachycardia syndrome; TTT, tilt table test.
signs consistent with POTS who do not meet diagnostic criteria for POTS.\textsuperscript{32} Other studies estimate prevalence rates from 25\%\textsuperscript{34} to upward of 40\% to 69\% in individuals with PASC.\textsuperscript{32} Given these data and the overlapping symptoms between POTS and PASC, the American Autonomic Society (AAS) has called for increased research funding to investigate post-COVID POTS and clinical resources to provide care to patients with new-onset autonomic dysfunction following SARS-CoV-2 infection.\textsuperscript{35}

**ASSESSMENT RECOMMENDATIONS FOR AUTONOMIC DYSFUNCTION IN PATIENTS WITH PASC**

Considering the wide variety of symptoms and signs of autonomic dysfunction, patients with PASC may present a diagnostic challenge. The PASC Collaborative consensus guidance statement assessment recommendations offer an approach to history, physical exam, laboratory tests, and diagnostic investigations that can aid with the diagnosis of autonomic dysfunction in patients with PASC (see Table 3).

### Assessment recommendations discussion

#### Patient history

Because patients with PASC typically present with a number of symptoms, clinicians should identify the most disabling autonomic signs and symptoms, which include dizziness, lightheadedness, palpitations, tachycardia, presyncope, syncope, orthostatic intolerance, exercise intolerance, cognitive dysfunction, and fatigue (Table 2). The onset of these symptoms in relation to the acute SARS-CoV-2 infection should be recorded due to several possible modes of onset: (1) symptoms may develop as part of the acute SARS-CoV-2 infection and persist after resolution of viral infection; (2) symptoms may develop within the subacute period (days to weeks) of recovery from acute SARS-CoV-2 infection; and (3) symptoms may develop with delayed onset, typically within 1 to 3 months following acute infection. Review of the course and treatment of acute SARS-CoV-2 infection, hospitalization, and current medications with side effects—such as orthostatic intolerance, orthostatic hypotension or resting or postural tachycardia—and personal and family history of autoimmune and autonomic disorders should be obtained.

### Initial evaluation

Orthostatic intolerance is the hallmark of common autonomic disorders. Because dysfunction of the ANS can affect multiple organs and body systems,
A neurologic exam including pinprick and temperature sensation is recommended to help identify small fiber neuropathy. Other potential signs of small fiber neuropathy include autonomic dysfunction such as dizziness, lightheadedness, palpitations, presyncope, syncope, orthostatic intolerance, exercise intolerance, cognitive dysfunction, and fatigue (see Table 2).

Similarly, some patients with PASC-related autonomic dysfunction may present with symptoms suggestive of anxiety, and although anxiety and other neuropsychiatric manifestations can occur as part of PASC, it is important not to attribute autonomic symptoms to those of generalized anxiety, depression, or panic disorder, which can lead to a missed diagnosis and opportunity for treatment of the autonomic disorder. In one study, a survey of patients with POTS unrelated to COVID-19 reported that 75% of patients have been misdiagnosed by a physician prior to a diagnosis of POTS. This same study reported that of the survey respondents, 77% (n = 3471) encountered a physician who suggested their symptoms were due to a psychiatric or psychological problem before they were diagnosed with POTS.

Many patients with POTS have small fiber neuropathy, which has also been found in patients with PASC. A neurologic exam including pinprick and temperature sensation is recommended to help identify small fiber neuropathy. Other potential signs of...
autonomic dysfunction include abnormal pupillary exam with dilated pupils that are poorly responsive to light, and evidence of acrocyanosis—a purplish-blue discoloration of the lower extremities due to, in part, to blood pooling. Acrocyanosis may also occur in patients with Raynaud’s disease, other connective tissue disorders, and erythromelalgia and may sometimes point toward autoimmune etiology. Assessment for joint hypermobility with the Beighton scale may be warranted in some patients with new or pre-existing joint pain or joint hypermobility to identify hypermobility spectrum disorders and hypermobile Ehlers-Danlos syndrome (EDS), which are highly prevalent in patients with POTS and other autonomic disorders. Similarly, flushing, urticaria, and dermographism may be present on skin examination of patients with autonomic dysfunction and mast cell hyperactivity, which may accompany POTS, EDS, and PASC.

A 10-minute stand test, in addition to a thorough examination of the cardiovascular and neurological systems, is recommended. The procedure for a 10-minute stand test is as follows:

1. Have the patient lie down quietly for 5 minutes. Obtain the blood pressure and heart rate using a sphygmomanometer on the upper arm.
2. With the patient standing quietly without moving or talking, obtain blood pressure and heart rate using a sphygmomanometer on the upper arm within 3, 5, 7, and 10 minutes of standing.
3. Record patient-reported symptoms throughout the test. (Appendix A contains a sample symptom-reporting table.)
4. Caution should be exercised for highly symptomatic patients who are unable to safely stand for 10 minutes due to orthostatic intolerance or neuromuscular disorders with impaired mobility.

If the 10-minute stand test confirms a diagnosis of POTS, NCS, OH, or OI (see Table 1) then no further confirmation via a tilt table test is necessary. If a 10-minute stand test is inconclusive or unremarkable in a patient with suspicion for an autonomic disorder, a tilt table test should be considered (see section on autonomic function tests). Clinicians may take into consideration any available patient generated data from wearable heart rate devices or monitors (Apple watch, Fitbit or similar devices) or the patient’s self-obtained 10-minute stand test performed at home. These data may help with the diagnosis of an autonomic disorder when an in-office 10-minute stand test is inconclusive. Note that a 10-minute stand test may provide variable results depending on the time of the day, the patient’s symptoms at the time of the appointment, hydration status, and other factors. When diagnosis is uncertain, or symptoms are progressing, other cardiovascular, neurologic, gastrointestinal, and genitourinary tests with possible referral to an autonomic specialist may be considered.

It is important to prioritize health equity for persons with pre-existing neurologic and autonomic disorders. Table 4 provides a summary of what is known about autonomic dysfunction in specific populations and provides clinical considerations for those populations. Autonomic dysfunction is associated with many different conditions that cause disability such as Parkinson disease, multiple sclerosis, spinal cord injury, traumatic brain injury, and diabetes mellitus. Depending on functional status of the individual, modifications may be required for physical exam and autonomic evaluation in the office setting. For example, some patients with impaired mobility, severe orthostatic intolerance, or spinal cord injury may be unable to complete a 10-minute stand test; therefore, modifications and special accommodations in the usual testing protocols may be needed for these patient populations.

Laboratory evaluation

Laboratory assessment should include a complete blood count (CBC), a comprehensive metabolic panel (CMP), and thyroid function tests (TFTs). Common vitamin and nutritional deficiencies in patients with autonomic symptoms and disorders include iron deficiency without anemia or mild anemia and vitamin B12 deficiency. Vitamin B12 and serum ferritin level can be obtained, and supplementation is recommended if deficiencies are noted. Additional tests for consideration include a morning serum cortisol to assess if adrenal insufficiency is contributing to syncope, presyncope, or low blood pressure. In addition, assessing basic markers of inflammation and autoimmunity, such as an antinuclear antibody (ANA), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), are recommended in patients with autonomic dysfunction in the setting of PASC.

If the patient is experiencing tachycardia, particularly in conjunction with dyspnea, obtaining a serum c-dimer is recommended to assess for pulmonary embolism, especially if symptoms developed within weeks of their acute SARS-CoV-2 infection, given an association between SARS-CoV-2 and thromboembolic events. Additional laboratory workup may be considered based on the results of initial laboratory tests, or if there are specific clinical features that warrant further investigation.

Autonomic function tests

When an autonomic disorder is suspected and previous testing, including a 10-minute stand test, is unrevealing, a tilt table test should be considered. In situations where the diagnosis is unclear or patients have
### TABLE 4  Health equity considerations and examples in post-acute sequelae of SARS-CoV-2 infection (PASC): Autonomic Dysfunction

| Category | Comment | What is known | Clinical considerations |
|----------|---------|---------------|-------------------------|
| **Disability**  
*Example: People with certain conditions that cause disability and autonomic dysfunction* | Individuals with pre-existing autonomic disorders require special consideration in the workup and management of autonomic dysfunction in PASC | The impact of PASC-related autonomic dysfunction should be considered early and often in individuals with possible baseline autonomic dysregulation. Autonomic dysregulation is known to occur in many different conditions that cause disability (e.g., Parkinson disease, multiple sclerosis, spinal cord injury [SCI], traumatic brain injury, and diabetes mellitus). As an example, autonomic dysreflexia is a well-documented complication of SCI and can be a medical emergency warranting urgent attention. In SCI, autonomic dysfunction may be affected by the level and/or severity of the initial injury. | Depending on functional status, modifications may be required for a 10-min stand test in the office setting (e.g., some patients with SCI may be unable to perform supine to sitting to standing orthostatic maneuvers). Thus, modifications in usual testing protocols may be needed for this population. The treatment of autonomic disorders in people with underlying SCI also requires careful consideration. For example, increasing fluids may affect bladder protocols such as frequency of intermittent catheterization. Exercise and activity prescriptions should take into account paralysis, autonomic symptoms, and other considerations (e.g., underlying heterotopic ossification or rotator cuff dysfunction). People with SCI and other patients who have complicated medical conditions combined with autonomic dysfunction may require longer visits and more health care personnel (e.g., PM&R physicians, nurses, physical therapists, psychologists, social workers) to deliver optimal care. |
| **Obesity**  
*Example: People diagnosed as overweight/obese* | Individuals who are overweight may have more severe COVID-19 acute infection and sequelae | Individuals who are overweight are at higher risk for COVID-19 infections and associated morbidity and mortality. Although research is still emerging, obesity may be a risk factor for PASC. While the effect of excess weight on PASC-related autonomic function is not currently known, obesity does have documented effects on sympathetic nervous system activity. | Although it is unknown whether obesity is a risk factor for PASC-related autonomic dysfunction, it is important to recognize that individuals who are overweight and experiencing autonomic symptoms may need special consideration from a rehabilitation perspective. For example, addressing weight loss strategies can be done within their system of care and considering their own social determinants of health (SDOH). Identifying and treating sleep apnea, which is associated with obesity, is an important component of enhancing autonomic regulation and improving symptoms of fatigue. Physical activity should be cautiously and appropriately (Continues) |
### TABLE 4 (Continued)

| Category | Comment | What is known | Clinical considerations |
|----------|---------|---------------|-------------------------|
| Racial/Ethnic Minority Groups  
Example: People who identify as Black (including African-American),  
American-Indian Alaska Native, Pacific Islander,  
Asian-American, and Mixed Race, and/or Latino/Hispanic (ethnicity) | Individuals who identify with historically, socially, or economically marginalized groups may be at higher risk for COVID-19 related morbidity and mortality | Throughout the pandemic, it has been documented that people who identify with racial/ethnic minority groups may be a higher risk for acute COVID-19 infection and more severe disease. PASC-related sequelae have been reported to increase with more severe acute infection and with more baseline comorbidities; race may also be a factor, though research is still emerging. Race is among the factors that have been reported to affect heart rate variability, including with Postural Orthostatic Tachycardia Syndrome (POTS). For example, while a majority of patients with POTS are young White/Caucasian women, a diagnosis of POTS should not be missed in patients who identify with other races or in male patients. | While the incidence of autonomic dysregulation in various populations of PASC is still unknown, rehabilitation clinicians should be aware that patients who identify with historically, socially, or economically marginalized groups may experience disparities in diagnosis and treatment. The impact of SDOH should also factor into evaluation and management strategies to manage autonomic disorders. Vigilance about recognizing autonomic dysfunction is important. Educating clinicians and patients about how to access specialized care when needed is vital. The impact of PASC-related autonomic dysfunction should be considered in persons from all racial/ethnic minority groups and efforts to improve symptoms, function and participation should be a priority. |
| Biologic Sex  
Example: Pregnancy | Sex differences should be considered for both the diagnosis and treatment of PASC-related autonomic disorders | Patients with POTS tend to present with a constellation of symptoms and the diagnosis is much more common in female adults (compared to male adults), typically occurring during childbearing years. There is a paucity of literature on PASC-related autonomic dysfunction during pregnancy in individuals with pre-existing or new symptoms. However, it is known that both pregnancy and COVID-19 infection may affect autonomic regulation. One survey study of patients with POTS showed challenges with diagnosis and multiple comorbidities. In this study, female patients with POTS were impacted more regarding challenges with diagnosis, symptom burden, and quality of life. There was significant diagnostic delay of POTS, including 2 years longer in female than male patients. | Among the medical community, there is limited awareness and recognition of autonomic conditions, inclusive of but not limited to POTS. POTS is a common autonomic disorder that is ideally managed by physicians and rehabilitation clinicians who recognize the heterogeneity of the syndrome and implement a tailored treatment approach. Enhancing clinical education may reduce diagnostic delays as well as improve access to care and outcomes. Clinicians should be aware of implicit (unconscious) sex-related bias as this may add to the challenges for female patients with POTS or another autonomic related dysfunction; importantly, a misdiagnosis with psychiatric or psychological disorders is common. In pregnant individuals, rehabilitation interventions such as exercise |
TABLE 4 (Continued)

| Category | Comment | What is known | Clinical considerations |
|----------|---------|---------------|-------------------------|
| Insurance | Insurance coverage, or lack thereof, should be considered when devising a treatment plan addressing autonomic-related issues in PASC. Encouraging patient engagement and addressing psychosocial factors may improve adherence with treatment recommendations | Autonomic disorders, including but not limited to POTS, are challenging to diagnose. This means that patients often undergo multiple evaluations and extensive medical testing. 56 For patients who are uninsured or underinsured, the cost of securing a diagnosis and undergoing appropriate treatment may not be feasible. Financial hardships associated with COVID-19 acute infections and PASC-related sequelae are being increasingly documented 57 | Clinicians should be aware of the cost of diagnostic and treatment interventions. Consider the value of diagnostic testing to rule in/out various conditions. Treatment interventions, such as physical therapy, may be limited by the cost of copayments and deductibles, even in patients who have medical insurance. Individuals with post-COVID POTS and other autonomic disorders may need to be referred to an autonomic specialty clinic as guided by the assessment recommendation statements (Table 3). 5 Social services or community groups may assist persons with finding local support. During the pandemic, there has been a broadening of insurance coverage for telemedicine services, including telephone visits and virtual visits online—leading to greater use of and access to these services. Telerehabilitation is evolving. 58 and patients have reported relatively high rates of satisfaction with |

Example: Individuals who are uninsured, underinsured, or cannot afford access to recommended healthcare services
progressive symptoms or symptoms refractory to treatment, consider referral to an autonomic specialist. Other specialized testing that can be considered (often under the guidance of an autonomic specialist) include a deep breathing test, Valsalva maneuver, quantitative sudomotor axon reflex test (QSART), thermoregulatory sweat test, and a skin biopsy for evaluation of small fiber neuropathy. It is important to note that access to autonomic specialists and the autonomic laboratories equipped to perform these tests is limited throughout the country, which may present a significant barrier to diagnostic evaluation in patients with suspected autonomic disorders.

Tilt table testing

Tilt table testing is recommended in patients presenting with autonomic symptoms with unremarkable in-office 10-minute stand test. Patients are laid in a supine position and then tilted upright to 60 to 70 degrees for at least 10 minutes while blood pressure and heart rate are monitored using both peripheral arterial volume-clamp measurements, confirmed with an automated cuff sphygmomanometer over the brachial artery, allowing for continuous beat-to-beat assessment during head-up tilt. If possible, all medications that may affect heart rate and blood pressure should be held for at least four half-lives prior to the tilt table test to minimize blunting of vital sign responses. A tilt table test can confirm a diagnosis of POTS, NCS, OH, and NCS. It is important to note that access to autonomic specialists and the autonomic laboratories equipped to perform these tests is limited throughout the country, which may present a significant barrier to diagnostic evaluation in patients with suspected autonomic disorders.

Deep breathing testing

Deep breathing testing is performed by having a patient take slow, deep breaths at a rate of six breaths/minute in the supine position. This test assesses the integrity of cardiovagal reflexes and the parasympathetic system. Heart rate is monitored with a single-lead ECG, and the difference between the heart rate at the end of expiration and the end of inspiration is calculated (maximal-minimum heart rate). An abnormal result is defined as a maximum-minimum heart rate less than the 5th percentile of age- and sex-adjusted normative data, and if present may suggest an autonomic neuropathy. Less than 10% of patients with POTS have been noted to have an abnormal deep-breathing test.

Valsalva maneuver

Valsalva maneuver is performed by a forceful attempt of exhalation against a closed airway and assesses cardiovagal responses. Like deep breathing, this test is performed in the supine position to limit the effects of gravitational stress. The patient is coached to forcefully exhale at a pressure of at least 40 mm Hg against a closed glottis for 10 seconds using a bugle-type mouth piece. Blood pressure and heart rate are recorded continuously as during tilt testing. Analysis of the blood pressure response to the Valsalva maneuver evaluates sympathetic adrenergic function, and analysis of the heart rate response evaluates cardiovagal function. There are four phases of the Valsalva maneuver, but
only late phase II and phase IV are evaluated for integrity of autonomic baroreflex function. Specifically, an increase in blood pressure during late phase II and a blood pressure overshoot in phase IV are expected, both of which represent peripheral vasoconstriction mediated by sympathetic adrenergic outflow. In patients with POTS, the Valsalva test is typically normal, although some patients may exhibit a hyperdynamic blood pressure response consistent with baroreflex hypersensitivity and a hyperadrenergic state.38

Quantitative sudomotor axon reflex testing (QSART) Quantitative sudomotor axon reflex testing (or QSART) assesses the post-ganglionic sudomotor (sweat) function by monitoring the sweat response to peripheral stimulation of sudomotor nerves. It is a diagnostic test for evaluation of small fiber neuropathy. An abnormal QSART has been noted in 33% to 63% of patients with POTS.38

Thermoregulatory sweat testing (TST) Thermoregulatory sweat testing (or TST) assesses the pre- and post-ganglionic sudomotor functions by assessing the sweat response to elevation in core body temperature. It can indicate distinct patterns of sweat loss in neurodegenerative autonomic disorders, such as pure autonomic failure, multiple system atrophy, and peripheral autonomic disorders, such as diabetic autonomic neuropathy and autoimmune autonomic ganglionopathy. Abnormal TST is seen in at least half of patients with POTS with a predominantly distal sweat loss pattern.28,38

Skin biopsy Skin biopsy is a minimally invasive in-office procedure using a punch biopsy kit. Obtained from the distal and proximal leg, the skin is evaluated for epidermal nerve fiber and sweat gland densities. Decreased epidermal nerve fiber density and/or decreased sweat gland density are highly prevalent in patients with POTS or PASC.37

Cardiac tests ECG, echocardiography, and ambulatory cardiac monitoring should be considered for patients presenting with autonomic dysfunction. If history and physical exam are suggestive of or consistent with cardiovascular disorders rather than autonomic dysfunction, we recommend cardiovascular evaluation as per the separately published PASC Collaborative consensus guidance statement on Cardiovascular Complications.18 In cases of diagnostic uncertainty and given the significant overlap between cardiac and autonomic symptoms, clinicians should have a low threshold for obtaining both cardiovascular and autonomic evaluations.

Activity performance measures Patients who are referred for rehabilitation therapies should be evaluated with objective measures of activity performance. These measures can be used to compare to healthy control values to help understand the degree of physical dysfunction and can help guide the initial activity prescription. They can then be repeated at follow-up visits to help quantify functional changes and guide progression of activity.

The measures should be individualized to the patient’s abilities, including consideration of modifications necessary to accommodate disability due to neurological or other impairment, fatigue with post-exertional malaise, autonomic dysfunction, pregnancy, or other limitations. Potential measures include a 30-second sit-to-stand test, 2-minute step test, and 6-minute walk test.71–77 Longer testing, such as the 6-minute walk test, may be more suited to be performed during a physical therapy evaluation as opposed to a clinic visit for time considerations. It is important to note that these tests may represent significant exertion and could exacerbate post-exertional symptoms. Alternative tests exist for patients requiring more in-depth assessment.

TREATMENT OF AUTONOMIC DYSFUNCTION IN PATIENTS WITH PASC Currently, evidence-based therapies and clinical guidance available for treatment of autonomic dysfunction specific to patients with PASC are lacking. Therefore, in this consensus guidance statement, we reference therapies that have been utilized for the management of POTS, OH, NCS, IST, and AN as applicable to PASC and post-COVID autonomic disorders. The therapeutic approach to autonomic disorders consists of non-pharmacologic and pharmacologic treatment modalities that are employed with the goal of reducing symptom severity and functional impairment. The treatment recommendations for autonomic dysfunction in patients with PASC are outlined in Table 5.

Treatment recommendations discussion Non-pharmacological treatment recommendations As best practices continue to emerge to address the symptoms of PASC-related autonomic dysfunction, non-pharmacological treatment recommendations that have been employed for treatment of POTS and other autonomic disorders unrelated to COVID-19 may assist in symptom management.
TABLE 5 Treatment recommendations for autonomic dysfunction in patients with PASC.

| No. | Autonomic dysfunction in PASC treatment recommendations |
|-----|---------------------------------------------------------|
| 1   | For individuals diagnosed with autonomic dysfunction, provide education on etiology and management including identification of exacerbating and remitting factors |
| 2   | For individuals presenting with autonomic dysfunction and no evidence of post-COVID cardiovascular complications or other contraindications such as congestive heart failure, pericarditis, myocarditis, coronary artery disease or hypertension, start non-pharmacologic management including: |
|     | • Increased fluid/salt intake: >3 L of fluid and >10 g of salt (4 mg of sodium) daily |
|     | • Compression garments (waist-high stockings and/or abdominal binder) |
|     | • Lifestyle management to include recognizing and avoiding symptom triggers and physical counterpressure maneuvers to mitigate orthostatic intolerance |
|     | • Patient education, psychological support and coping skills |
|     | • Consideration of discontinuation of medications or substances that may cause or exacerbate orthostatic intolerance, tachycardia or hypotension |
| 3   | For individuals with severe or persistent symptoms after a trial of non-pharmacologic measures, consider pharmacologic interventions |
|     | • First-line medications: low-dose beta blockers (e.g. propranolol or atenolol); fludrocortisone; midodrine |
|     | • Second-line medications: pyridostigmine; ivabradine; clonidine; methyldopa; modafinil, methylphenidate; selective serotonin reuptake inhibitors (SSRIs); serotonin and norepinephrine reuptake inhibitors (SNRIs); bupropion; dextroamphetamine |
| 4   | Individuals with autonomic dysfunction may benefit from personalized autonomic rehabilitation program interventions to reduce fatigue and gradually improve exertional tolerance. This may start with activities in a supine or sitting position. The intensity of rehabilitation activities should be carefully titrated to avoid post-exertional symptomatic exacerbation. See: Multi-Disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Fatigue in Post-Acute Sequelae of SARS-CoV-2 infection (PASC) Patients17 |
| 5   | Consider referring individuals experiencing treatment-refractory or progressive symptoms to an autonomic specialist. [https://americanautonomicsociety.org/physician-directory/http://dysautonomiainternational.org/page.php?ID=14](https://americanautonomicsociety.org/physician-directory/http://dysautonomiainternational.org/page.php?ID=14) |

1. **Salt supplementation**: Salt (sodium chloride) supplementation has been utilized as an effective non-pharmacologic therapy in patients with autonomic disorders, likely due to its effect on increasing plasma volume as reducing sympathetic overactivity.76,78 For individuals with PASC-associated autonomic dysfunction, salt supplementation of 7 to 10 g (2.8–4 mg) of sodium per day is recommended.20,76 Caution should be taken in recommending salt supplementation in those with a history of heart failure, altered renal function, or those with episodic or sustained elevated blood pressure. These individuals may require either a recommended daily allowance of sodium at 4 g per day or mild to moderate increase in salt intake.

2. **Fluid intake**: Water consumption should be increased to at least 3 L per day. It is recommended that water and salt be consumed together.76,78 Water without salt is not effective in sustained volume expansion. Another possible option is glucose-salt rehydration solutions, although their use has not been confirmed in clinical trials. Increased salt and fluid intake should be started prior to or concurrently with exercise.20 Caution should be taken in those with a history of cardiovascular or renal disorders.

3. **Compressive garments**: Compression garments are recommended for individuals with autonomic dysfunction to minimize venous pooling and central hypovolemia associated with orthostasis. For individuals with PASC who are experiencing orthostatic intolerance, waist-high lower body compression garments and/or accompanied by abdominal binders, 20 to 40 mm Hg or 40 to 60 mm Hg in strength, can be trialed.79,80 If found beneficial, compression garments may be worn during the daytime and removed at night.81

4. **Diet**: There is no evidence-based guidance on the dietary approaches to patients with PASC-related autonomic dysfunction. Low-histamine, gluten-free, dairy-free, low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAP) and plant-based diets have been anecdotally reported to be beneficial. A gluten-free diet was demonstrated to be beneficial in some patients with POTS.82 When considering dietary changes, the benefits of a particular diet need to be weighed against the risks, including vitamin or nutrition deficiencies. Diets may be individualized and targeted toward the patient’s specific set of symptoms and food sensitivities. A referral to a dietitian or nutrition specialist may be considered.83,84 Small frequent meals with salty snacks instead of three large meals may be better tolerated due to a reduction in post-prandial autonomic symptoms and heart rate and blood pressure variability.85,86

5. **Counterpressure maneuvers and head of the bed elevation**: Counterpressure maneuvers performed during prolonged sitting or standing may reduce the symptoms of NCS and OI, and head of the bed elevation can be helpful in patients with OH (three references in the comment). These techniques could offer inexpensive and low-risk treatment modalities aimed at managing orthostatic intolerance and may be useful in some patients with autonomic dysfunction.87

**Pharmacotherapy**

When non-pharmacologic therapy alone is ineffective or insufficient to result in improvement, pharmacologic...
treatment should be initiated. Table 6 summarizes pharmacotherapy options.

The choice of pharmacotherapy depends on the clinical presentation and the most disabling symptoms that the patient is experiencing. For example, if the patient exhibits significant postural or resting tachycardia in the absence of significant orthostatic hypotension, a beta blocker, such as propranolol 5 to 10 mg twice a day or atenolol 12.5 to 25 mg daily, should be considered.88,89 The starting dose of a beta blocker should be low because a high dose may result in hypotension, increased dizziness, and exacerbation of fatigue. Dosage can be increased according to therapeutic response while considering adverse effects.

If the patient has significant orthostatic intolerance accompanied by low blood pressure, then midodrine 2.5 to 5 mg three times a day or fludrocortisone 0.05 to 0.1 mg daily should be considered.88,89 Fludrocortisone requires about 2 weeks of administration to result in symptomatic improvement, whereas the effect of midodrine can be assessed within a few days after its initiation and dose escalation. The maximum dose of midodrine may be 30 to 40 mg daily, whereas low doses of fludrocortisone, up to 0.2 mg daily, are typically used for patients with autonomic disorders.88,89 As with beta blockers, starting one medication at a time at a low dose and increasing slowly to a maximum therapeutic effect is recommended because patients with

### Table 6: Pharmacological treatment options for autonomic dysfunction

| Medication | Dose | Indications | Side effects/precautions |
|------------|------|-------------|--------------------------|
| Propranolol | 5–10 mg BID to QID | POTS, IST, OH, NCS, episodic hypertension | Bradycardia, hypotension, fatigue, depression, asthma exacerbation |
| Atenolol | 12.5–25 mg QD to BID | | |
| Fludrocortisone | 0.05–0.2 mg QD | NCS, OH, POTS, hypotension | Hypokalemia, edema, headache |
| Midodrine | 2.5–10 mg TID to QID | NCS, OH, POTS, hypotension | Scalp paresthesia, piloerection, supine hypertension |

2nd Line

| Medication | Dose | Indications | Side effects/precautions |
|------------|------|-------------|--------------------------|
| Pyridostigmine | 30–60 mg BID to TID | POTS, OH, AN, GI dysmotility with constipation | Diarrhea, muscle twitching |
| Ivabradine | 2.5–7.5 mg BID | POTS, IST | Visual disturbance, headache, hypertension |
| Methylphenidate | 5–10 mg BID to TID | NCS, OH, POTS, cognitive dysfunction, fatigue | Insomnia, headache, tachycardia |
| Modafinil | 50–200 QD to BID | Cognitive dysfunction, hypersonnelence, fatigue | Tachycardia, insomnia |
| Clonidine | 0.05–0.2 mg QD to TID or long-acting patch | POTS, episodic hypertension and/or tachycardia, anxiety | Hypotension, fatigue, brain fog |
| Methyldopa | 125–250 mg BID | POTS, episodic hypertension and/or tachycardia, anxiety | Hypotension, fatigue, brain fog |
| Fluoxetine | 10–40 mg QD | NCS, anxiety/depression | Anxiety, insomnia, nausea |
| Bupropion | 75–150 mg QD to BID | POTS, NCS, fatigue, depression, hypersonnia | Nausea, anxiety, insomnia, decreased seizure threshold |
| Duloxetine | 20–60 mg QD | NCS, OH, neuropathic pain, depression | Nausea, hypertension, Increased perspiration |
| Droxidopa | 100–600 mg TID | FDA-approved for neurogenic OH; NCS and POTS in some cases | Headache, hypertension, tachycardia, nausea |

Other

| Medication | Dose | Indications | Side effects/precautions |
|------------|------|-------------|--------------------------|
| Desmopressin | 0.1–0.2 mg QD prn | POTS, OH | Hypotremia, edema |
| IV saline | 1–2 L IV over 1–4 h prn | Decompensation of POTS, NCS, OH with dehydration, infection or GI dysmotility disorder | Avoid chronic frequent use that can lead to placement of central catheters, which can cause thrombosis and infection |
| IVIG | 1–2 g/kg/month IV weekly to every 4 weeks | Severe, treatment-refractory POTS, SFN, and AN with positive autoimmune markers | Flu-like symptoms, headache, aseptic meningitis |

Abbreviations: AN, autonomic neuropathy; BID, twice daily; TID, three times daily; FDA, Food and Drug Administration; GI, gastrointestinal; IST, inapparent sinus tachycardia; IV, intravenous; IVIG, intravenous immunoglobulin; NCS, neurocardiogenic syncope; OH, orthostatic hypotension; POTS, postural orthostatic tachycardia syndrome; prn, as-needed; QD, once daily; QID, four times daily; SFN, small fiber neuropathy.
POTS and other autonomic disorders can be sensitive to medications and their adverse effects.

Other medications used for autonomic dysfunction, include pyridostigmine, ivabradine, clonidine, modafinil, methylphenidate, methyldopa, or selective serotonin reuptake inhibitors (SSRIs)/serotonin and norepinephrine reuptake inhibitors (SNRIs).88,89 The choice of medication depends on which clinical symptoms or signs need to be addressed. For example, if the patient has orthostatic intolerance in the setting of normal or elevated blood pressure, pyridostigmine may be utilized. If the patient has labile blood pressure and symptoms of episodic sympathetic overactivity, such as tachycardia, diaphoresis, anxiety and polyuria, then clonidine or methyldopa may be tried.

For patients with concurrent depression, anxiety, obsessive–compulsive symptoms, or neuropathic pain, a trial of a low-dose SSRI or SNRI, such as duloxetine, could be beneficial.88,89 Bupropion, in particular, has shown some benefit in reducing fatigue in patients with POTS.88,89 Given significant fatigue and cognitive symptoms (i.e., “brain fog”) in patients with PASC, a trial of modafinil, methylphenidate, or other stimulants can be considered, with caution in patients with POTS or with sleep disturbance because stimulants may worsen tachycardia and insomnia. In such cases, a low dose of a beta blocker in combination with a stimulant could be employed. In patients who are unable to tolerate beta blockers due to hypotension, fatigue, respiratory disorders, or depression, ivabradine can be used to treat tachycardia.88,89

Droxidopa is approved by the U.S. Food and Drug Administration (FDA) for treatment of neurogenic OH and can be beneficial in patients with post-COVID OH and some patients with POTS.88,89 Desmopressin 0.1 mg orally can also be utilized in certain cases on an as-needed basis for orthostatic intolerance. Intravenous immunoglobulin therapy can be considered in treatment-refractory patients with severe POTS, small fiber neuropathy, autonomic neuropathy, and other autonomic disorders and serologic evidence of autoimmunity (including, but not limited to, elevated serum ANA, anti-phospholipid antibodies, ESR, CRP, and others) or comorbid autoimmune disorders.90 In addition, intravenous saline, usually 1 to 2 L over 1 to 2 hours, could be used on as-needed basis for acute exacerbation of POTS or in patients with significant gastrointestinal dysfunction who are unable to maintain oral hydration.89 Chronic use of intravenous fluids is not recommended due to a risk of infection and thrombosis associated with central intravenous line placement.89 Non-invasive vagus nerve stimulator, currently under investigation for treatment of POTS, may be considered, given its potential anti-inflammatory effect via activation of the vagus nerve and reduction of pro-inflammatory cytokines.91,92

Treatment of common comorbidities associated with autonomic dysfunction, such as migraine headache, neuropathic pain, sleep disturbance, gastrointestinal dysfunction, and mast cell hyperactivity-related allergies and food sensitivities may indirectly alleviate autonomic dysfunction by reducing symptom burden caused by the associated comorbidities. Antihistamines, such as loratadine, cetirizine, fexofenadine, and famotidine, and mast cell stabilizing agents, such as cromolyn sodium and ketotifen, may be treatment options considering that patients with PASC may display mast cell activation symptoms.41 Low-dose naloxone may be considered for treatment of neuropathic pain, chronic joint pain, fatigue, and other pain that may occur in patients with PASC-related autonomic dysfunction.93,94 If pre-diabetes or diabetes is discovered as part of the comprehensive evaluation of PASC, treatment of hyperglycemia should be implemented under the guidance of a primary care physician. Sex differences should be considered in treatment of PASC-related autonomic disorders. In particular, there is a paucity of literature on PASC-related autonomic dysfunction during pregnancy in individuals with pre-existing or new symptoms. Symptoms of POTS during and after pregnancy are typically variable, and both non-pharmacologic and pharmacologic management may need to be adjusted (e.g., fluid and salt requirements and medications) during pregnancy and afterward if the patient is breastfeeding.95,96

Rehabilitation therapies

Coordination with a multidisciplinary team that includes Physical Medicine and Rehabilitation (PM&R) physicians, occupational therapists, and vocational and psychology services can help to create the functional adaptations that allow patient to resume their normal activities and roles while recovering from PASC. If PM&R physicians are available, they are experts in leading multidisciplinary rehabilitation teams and can help to coordinate the care and the variety of interventions needed to treat medically complex patients. Interventions may include the above-mentioned pharmacologic and non-pharmacologic treatments as well as physical and occupational therapy, neuropsychology, nursing, and other specialties. Part of a functional assessment and treatment program includes the assessment of the patient’s pre-morbid and current level of function which are then considered in the context of prescribing goal-directed therapy.

Physical therapists who are knowledgeable about autonomic dysfunction and related diagnoses ensure that patients tolerate and benefit from prescribed activity/exercise-related interventions and help with mobility compensation, including evaluating architectural accommodations, and considerations of wheeled mobility or the use of assistive devices such as rollators or canes. Occupational and physical therapists are instrumental in
employing pacing strategies and prescribing adaptive equipment that can improve function and participation levels. For example, activities of daily living (ADL) adaptations can include items such as long-handled reaching devices and other equipment to allow for activities so that bending, stooping, and standing can be reduced for individuals who are challenged by these activities. In coordination with PM&R physicians and therapists, automation and home adaptations can help patients to deal with issues of fatigue by conserving energy, even while the rehabilitation program works to restore endurance.

The entire therapy and physician team working with vocational rehabilitation can help patients to deal with challenges in the workplace (both structural and human-resource based) to restore the ability to work with reasonable accommodations in line with the Americans with Disabilities Act (ADA) and allow for return to work. Finally, neuropsychological interventions can help patients deal with the anxiety, depression, and coping mechanisms they may face when encountering a new disability related to PASC. Although traditional approaches to prescribing exercise in individuals with autonomic dysfunction and related diagnoses (e.g., POTS, OI, OH, and others) have suggested progressive graded aerobic and resistance-training exercise as a gold standard intervention, more recent research into this topic has highlighted significant concerns for the propensity of graded aerobic exercise programs to trigger worsened fatigue, symptom exacerbation, and autonomic dysfunction.

Specifically, one of the hallmarks of autonomic dysfunction in PASC is the presence of post-exertional symptom exacerbation or post-exertional malaise. Post-exertional symptom exacerbation suggests that although an individual may appear to tolerate an intervention during performance of the task, symptoms may flare for hours to days following the exercise. In one study, 86% of individuals diagnosed with PASC reported physical exertion as a cause for symptom exacerbation. Prior to the initiation of an exercise program, individuals with autonomic dysfunction related to PASC should undergo a comprehensive medical evaluation, as described earlier, which should take into account the propensity of physical exertion to lead to symptom exacerbation, and appropriately screen for post-exertional symptoms.

1. **Breathwork exercise**: Sympathetically mediated hypocapnia with orthostasis has been largely reported and is suspected in hypocapnia experienced by individuals with autonomic dysfunction. Furthermore, hypocapnia has been reported in individuals with PASC. Although the underlying mechanism is under further investigation, structured breathing exercise should be considered to address both autonomic and hyperventilation-mediated root causes of hypocapnia.

2. **Symptom-titrated physical activity/movement**: The goal of rehabilitation therapy is to promote symptom stabilization and to progress slowly toward improved activity tolerance without PASC symptom exacerbation. Symptom-titrated physical activity progression is recommended as part of a rehabilitation intervention. Rehabilitation therapists should not aim to “push” patients through symptoms or encourage physical work exceeding a patient’s tolerance. For patients with severe symptoms of autonomic dysfunction, post-exertional symptom exacerbation, or patients who that cannot tolerate upright activities, low-intensity activity started in the supine position and slowly progressing to upright activities over time is recommended. A sample rehabilitation program exemplifying this approach to PASC-related dysautonomia rehabilitation is provided below.

3. **Functional restoration**: One of the major limitations for individuals with PASC and autonomic dysfunction is the overall functional limitations that prevent normal return to activity and life functions. Key among these are limitations of mobility and inability to resume normal activities of daily living (or ADLs) and instrumental activities of daily living (IADLs). ADLs include tasks such as bathing, dressing, and eating, and IADLs include higher level activities such as shopping, housekeeping, driving, and other normal activities of life. A final level of loss of function can be the inability to return to school or work. Restorative or adaptive therapies to allow for vocational recovery are also important considerations.

**Sample rehabilitation program**

Here we provide a sample rehabilitation program that can be trialed with patients who are experiencing autonomic dysfunction in the setting of PASC. It is important to note that research related to physical rehabilitation in patients with PASC is still in the early stages, and other rehabilitation programs may also be appropriate.

Initiate the rehabilitation program with supine-based therapeutic movements including symptom-titrated active range of motion with focus on open chain activity (for example, heel slides, active range of motion hip adduction, straight leg raises). The term “symptom titration” implies that all interventions are scaled not based on intensity, but rather based on how a patient’s symptoms respond to the activity. Tolerance to intervention can be assessed using rate of perceived exertion (RPE), such as the BORG Scale and visual analog scale (VAS) of patient symptoms. Should the symptom VAS exceed a three-point change or RPE exceed “fairly light” on the BORG RPE scale from within the session baseline, movement therapy should be stopped. Therapeutic exercises should be prescribed on time-based intervals rather than sets/
repetitions to allow patients to implement energy-conservation strategies and promote symptom-titrated activity.

Supine movement should be progressed to upright activity after a minimum of 2 weeks so long as no symptom exacerbation is reported. Should post-exertional symptom exacerbation be reported (either within the session or in the hours to days following), interventions should be evaluated for exacerbating factors and the intensity modified/downgraded accordingly. Upright-based movement should continue to include open chain movements with the introduction of isometric exercises such as seated hip adduction (squeezing knees together). Because active range of motion–based interventions are tolerated, rehabilitation therapists may introduce ambulatory intervals to progress intervention. Heart rate and age-predicted heart rate max should not be utilized in the preliminary stages of walking intervals to scale aerobic exercise because traditional metrics of mild-to-moderate intensity exercise may not be tolerated in this cohort. Paced activity should be introduced with adequate rest between intervals. RPE and VAS of primary symptoms should continue to guide symptom-titrated activity and intensity of therapy interventions.

The intensity of interval training should be progressed over the course of a minimum of 6 weeks if symptoms remain stable and the patient tolerates. Pacing principles and energy-conservation strategies are pivotal to successful participation in rehabilitation therapy and should be reinforced continuously.

As patients continue to tolerate progressive symptom-titrated activity, more traditional forms of autonomic therapy can be introduced. Moderate-intensity aerobic interventions or similar traditional autonomic rehabilitation protocols (such as use of the Levine protocol) should be considered with the understanding that not all patients will be able to progress this far, and ongoing evaluation of activity tolerance is required. Patients may continue performing symptom-titrated movement interventions as tolerated.

Disability considerations

PASC can be considered a disability under the ADA, Section 504 and Section 1557, if it substantially limits at least one major life activity. It is imperative that patients with autonomic dysfunction related to PASC have their symptoms and other validated measures documented in the medical record and followed over time. As discussed in this consensus guidance statement, PASC-related autonomic dysfunction should be evaluated with a neurological examination and a 10-minute stand test, as well as a tilt table test and other autonomic function tests, if necessary. These evaluations should be submitted in support of getting disability benefits approved, especially if a patient’s autonomic dysfunction is expected to last at least 12 months.

Workers’ compensation companies and disability insurers need to acknowledge the disability that can occur when workers have PASC-related autonomic dysfunction. Employers are required to provide reasonable accommodations to employees with disabilities. Individuals with PASC-related autonomic dysfunction may need their clinical team’s assistance with requesting special accommodations from their employer. These accommodations may include flexible work schedule, periodic rest breaks, remote work, seated or reclining workstations, accessible parking, ability to have fluids at the workstation, and use of a fan at a workstation. This list is not an exhaustive list of accommodations for individuals with PASC-related autonomic dysfunction; other reasonable accommodations may be needed to address specific symptoms that may be interfering with the employee’s ability to work.

SUMMARY

Individuals with PASC commonly present with symptoms of autonomic dysfunction and should undergo a clinical evaluation for autonomic disorders. A comprehensive treatment program including non-pharmacologic, pharmacologic, and rehabilitative interventions is often needed to manage autonomic dysfunction and improve functional status. This guidance statement is designed to help clinicians currently treating individuals with PASC-related autonomic disorders by presenting evidence-based recommendations as well as recommendations based on the collective experience of the PASC Collaborative.

FUTURE DIRECTIONS

Although COVID vaccines may decrease the risk of PASC, breakthrough cases of COVID and subsequent PASC have been reported in fully vaccinated individuals, as well as observed in clinical practice. It is important to note that a number of patients with PASC experience temporary or permanent improvement in symptoms after immunization with COVID vaccines. In an early post-vaccination study to assess changes in the trajectory of long COVID symptoms in adults infected with SARS-CoV-2, the incidence of symptoms decreased after both the first and second vaccination doses. This study suggests that vaccination may reduce the burden of both SARS-CoV-2 and PASC in adults. In contrast, a retrospective cohort study did not find COVID vaccines to be protective against PASC in breakthrough cases. Further studies are needed to determine whether COVID vaccines decrease the incidence of PASC in vaccinated individuals after breakthrough infection,
vaccination remains one of the most important public health measures to mitigate the pandemic.

These PASC Collaborative guidance statements are preliminary. Studies that investigate autonomic dysfunction in patients with post-COVID symptoms are needed to determine what subset of patients with PASC have autonomic dysfunction. At this time, it is unknown whether post-COVID autonomic disorders are similar to those that can arise after other viral infections or whether these represent a distinct phenotype unique to SARS-CoV-2 virus. Future studies are also needed to determine the biomarkers as well as appropriate diagnostic, prognostic, and therapeutic approaches to patients with post-COVID autonomic dysfunction. Specialized rehabilitation programs, non-pharmacologic management (including individualized dietary and exercise regimens), and pharmacologic treatment (including immunotherapy), require further investigation in clinical trials. As new studies emerge, the PASC Collaborative may require a re-evaluation of the assessment and treatment clinical recommendations in order to provide the most up-to-date evidence-based patient care for individuals with PASC.

Health equity statement

The American Academy of Physical Medicine and Rehabilitation (AAPM&R) recognizes the need to support equitable access to rehabilitation care for individuals with Post-Acute Sequelae of SARS CoV-2 infection (PASC). The AAPM&R states that equitable access to care includes: (1) timely and local patient access to multidisciplinary care; (2) addressing inequities in the United States health system that result in diminished access to sustained quality care because of structural racism or socioeconomic factors; and (3) strengthened safety-net care, including disability evaluation and benefits.123

Each of the AAPM&R’s PASC guidance statements were produced by a diverse and multidisciplinary team of subject matter experts with patient input. Although an in-depth discussion of health equity issues is beyond the scope of the PASC guidance statements, each one highlights health equity concerns and refers readers to other publications and resources. The term “health equity” has many different definitions, which generally focus on ensuring that every person is able to achieve the highest level of health and function. For example, the CDC defines health equity as the opportunity for people to fulfill their full health potential and states that people should not be disadvantaged from achieving their potential because of social position or other socially determined circumstances.124 The Centers for Medicare & Medicaid Services (CMS) uses the definition established in Executive Order 13985, issued on January 25, 2021, which states that equity is “the consistent and systematic fair, just, and impartial treatment of all individuals, including individuals who belong to underserved communities who have been denied such treatment, such as Black, Latino, and Indigenous and Native American persons, Asian Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality.”125 There are many root causes for health disparities, some of which fall under the categories within social determinants of health (SDOH). Examples of SDOH include but are not limited to socioeconomic status, neighborhood, availability and access to healthy food, and access to a high-quality education.

In addition to advocating for equitable access to rehabilitation care for all persons with PASC, the AAPM&R supports four “Principles of Inclusion and Engagement” which include: (1) valuing diverse group composition (a diverse group is more representative of AAPM&R’s membership and volunteers may be selected as a member of a particular community to enhance diversity of thought and experiences); (2) mutual respect (cultivating a receptive space for differing opinions and viewpoints); (3) talent and skill-based selection for leadership opportunities (ensuring that broad criteria of diversity of experience, talent, and knowledge are incorporated and removing barriers to involvement that support an equitable environment); and (4) comprehensive collaboration (building community among various member constituent and bringing together different perspectives).126 Readers of the PASC guidance statements are encouraged to consider the recommendations through the lens of health equity in order to improve access to rehabilitation care for all individuals with PASC.

ACKNOWLEDGMENTS

The content of this Multi-Disciplinary Consensus Guidance Statement was developed in consultation with the
American Academy of Physical Medicine and Rehabilitation (AAPM&R) PASC Multi-Disciplinary Collaborative, comprising 35 PASC Clinics ([www.aapmr.org/PASC-guidance](http://www.aapmr.org/PASC-guidance)) or institutions that contributed to the development of the consensus statements via individuals working in their Post COVID/PASC Clinics or from their unique expertise in the assessment and treatment of PASC. The views and opinions expressed by Collaborative participants are their own and do not reflect the view of any organization. This consensus guidance statement reflects a Writing Group collaboration where the clinical leads are listed in the first and senior author positions and the remaining writing group members are listed alphabetically. This consensus guidance statement reflects input from patient communities, and the authors thank the following organizations and individuals for their input during the Collaborative writing process: the Patient-Led Research Collaborative, Angela Meriquez Vazquez, MSW, Long Covid Patient and Advocate, and Lauren Nichols, Long Covid Patient and Chronic Illness Advocate. The authors would like to specifically acknowledge the contributions of the PASC Collaborative Co-Chairs: Benjamin Abramoff, MD, MS; Eric Herman, MD; and Jason Maley, MD, MS. We would also like to acknowledge and extend a special thank you to Kavitha Neerukonda, JD, MHA and Michael Graves, AAPM&R, for their relentless efforts in the formation of the PASC Collaborative and directing the constantly evolving aspects of this work.

**FUNDING INFORMATION**

The work of the writing committees is supported exclusively by AAPM&R without commercial support. All participants were required to disclose relationships with industry and other entities.

**DISCLOSURES**

Please note that a number of authors (M. Verduzco-Gutierrez, J. Silver, MN Bartels, M. Miglis, and S. Blitshteyn) have disclosed funding from organizations and institutions for broader areas of research and expertise, but not in conflict with this work. The only author receiving funding for this specific manuscript is S. Sampsel, who is under contract to AAPM&R to support the writing and submission of each PASC Collaborative consensus guidance statement.

**ORCID**

Svetlana Blitshteyn ([https://orcid.org/0000-0002-3982-2031](https://orcid.org/0000-0002-3982-2031))

Jonathan H. Whiteson ([https://orcid.org/0000-0002-0741-8093](https://orcid.org/0000-0002-0741-8093))

Alba Azola ([https://orcid.org/0000-0002-9578-2898](https://orcid.org/0000-0002-9578-2898))

Tae Chung ([https://orcid.org/0000-0002-0270-5181](https://orcid.org/0000-0002-0270-5181))

Talya K. Fleming ([https://orcid.org/0000-0002-2034-8253](https://orcid.org/0000-0002-2034-8253))

Mitchell G. Miglis ([https://orcid.org/0000-0001-8488-0313](https://orcid.org/0000-0001-8488-0313))

Sarah Sampsel ([https://orcid.org/0000-0002-7496-8482](https://orcid.org/0000-0002-7496-8482))

Julie K. Silver ([https://orcid.org/0000-0001-9711-0713](https://orcid.org/0000-0001-9711-0713))

Monica Verduzco-Gutierrez ([https://orcid.org/0000-0003-0964-5908](https://orcid.org/0000-0003-0964-5908))

David Putino ([https://orcid.org/0000-0002-2232-3324](https://orcid.org/0000-0002-2232-3324))

**REFERENCES**

1. Collins FS. NIH launches new initiative to study “Long COVID”. National Institutes of Health. February 23, 2021. Accessed March 30, 2022 via [https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covidence](https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covidence)

2. The Center for Disease Control. Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance. June 14, 2021. Accessed March 30, 2022 via [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-background.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-background.html)

3. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021; Accessed 01/18/22 via [https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1)

4. López-León S, Wegman-Ostrosky T, Pereiman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. SSRN Electron J. 2021;11(1):1-12. doi:10.2139/ssrn.3769978

5. Larsen NW, Stiles LE, Miglis MG. Preparing for the long-haul: autonomic complications of COVID-19. Autoin Neurosci. 2021; 235:102841. doi:10.1016/j.autneu.2021.102841

6. Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285(4):352-366. doi:10.1111/joim.12852

7. Proal AD, VanElzakker MB. Long COVID or Post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. doi:10.3389/fmicb.2021.698169

8. Peluso MJ, Lu S, Tang AF, et al. Markers of immune activation and inflammation in individuals with Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224(11):1839-1848. doi:10.1093/infdis/jiab490

9. Townsend L, Dyer AH, Naughton A, et al. Longitudinal analysis of COVID-19 patients shows age-associated T cell changes independent of ongoing ill-health. Front Immunol. 2021;12:676932. doi:10.3389/fimmu.2021.676932

10. Charfeddine S, Ibn Hadj Amor H, Jdidi J, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745758. doi:10.3389/fcvm.2021.745758

11. Weinstock LB, Brook JB, Walters AS, et al. Mast cell activation and associated activity limitation, using UK Coronavirus COVID-19 condition by a Delphi consensus, 6 October 2021; Accessed 01/18/22 via [https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1)

12. Novak P, Mukerji SS, Alabsi HS, et al. Multisystem involvement in Post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. doi:10.3389/fmicb.2021.698169

13. CDC/National Center for Health Statistics. Nearly One in Five American Adults Who Have Had COVID-19 Still Have “Long COVID”. Atlanta, GA. Accessed July 25, 2022 via [https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm](https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm)

14. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 3 February 2022. Estimates of the prevalence of self-reported long COVID and associated activity limitation, using UK Coronavirus...
(COVID-19) Infection Survey data. Accessed April 18, 2022 via https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bitapments/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infec\ntionintheuk/7april2022

15. Herrera JE, Niehaus WN, Whiteson J, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. PM R. 2021;13(9):1027-1043. doi: 10.1002/pmrj.12684

16. Fine JS, Ambrose AF, Didehbani N, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022;14(1):96-111. doi: 10.1002/pmrj.12745

17. Maley JH, Alba GA, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022;14(1):77-95. doi: 10.1002/pmrj.12744

18. Whiteson JH, Azola A, Barry JT, et al. Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2022;14(7):855-878. doi: 10.1002/pmrj.12859

19. Maley JH, Sampsel S, Abramoff BA, Herman E, Neerukonda KV, Mikkelson ME. Consensus methodology for the development of postacute sequelae of SARS-CoV-2 guidance statements. PM R. 2021;13(9):1021-1026. doi: 10.1002/pmrj.12670

20. Shelden RS, Grubb BP II, Olshansky B, et al. Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(12):e41-63.

21. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. doi: 10.1007/s10286-011-0199-5

22. Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. EP Europace. 2019;21(2):194-207. doi: 10.1093/europace/euy128

23. Benarocco EE. Physiology and pathophysiology of the autonomic nervous system. Continuum. 2020;26(1):12-24. doi: 10.1212/CON.0000000000000817

24. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex–linking immunity and metabolism. Nat Rev Endocrinol. 2012;8(9):743-754. doi: 10.1038/nrendo.2012.189

25. Pongratz G, Straub RH. The sympathetic nervous response in inflammation. Arthritis Res Ther. 2014;16(6):504. doi: 10.1186/s13075-014-0504-2

26. Radin JM, Quer G, Ramos E, et al. Assessment of prolonged physiological and behavioral changes associated with COVID-19 infection. JAMA Netw Open. 2021;4(7):e2115959. doi: 10.1001/jamanetworkopen.2021.15959

27. Stute NL, Stickford JL, Province VM, et al. COVID-19 is getting on our nerves: sympathetic neural activity and haemodynamics in young adults recovering from SARS-CoV-2. J Physiol. 2021;599(18):4269-4285. doi: 10.1113/JPH218888

28. Thieben MJ, Sandroni P, Stetten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 2007;82:308-313. doi: 10.4065/82.3.308

29. Blitshtein S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):205-211. doi: 10.1007/s12026-021-09815-5

30. Bisaccia G, Ricci F, Recce V, et al. Post-acute sequelae of COVID-19 and cardiovascular autonomic dysfunction: what do we know? J Cardiovasc Dev Dis. 2021;8(11):156. doi: 10.3390/jcdd8110156

31. Aranyó J, Bazan V, Lidós G, et al. Inappropriate sinus tachycardia in post-COVID-19 syndrome. Sci Rep. 2022;12(1):298. doi: 10.1038/s41598-021-03831-6

32. Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31(3):385-394. doi: 10.1007/s10286-021-00803-8

33. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019

34. Ladlow P, O’Sullivan O, Houston A, et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm. 2021;19(4):613-620. doi: 10.1016/j.hrthm.2021.12.005

35. Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome: an American autonomic society statement. Clin Auton Res. 2021;31(3):365-368. doi: 10.1007/s10286-021-00798-2

36. Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey. J Intern Med. 2019;286(4):438-448. doi: 10.1111/joim.12895

37. Novak P, Mukerji SS, Alabsi HS, et al. Multisystem involvement in Post-acute sequelae of coronavirus disease 19. Ann Neurol. 2022;91(3):367-379. doi: 10.1002/ana.26286

38. Goodman BP. Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci. 2018;215:12-19. doi: 10.1016/j.autneu.2018.04.004

39. Heidrich F. Functional vascular diseases: Raynaud’s syndrome, acrocyanosis and erythromelalgia. Vasa. 2010;39(1):33-41. doi: 10.24030/1526-a00003

40. Wang E, Ganti T, Voao E, Kohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. Allergy Asthma Proc. 2021;42(3):243-246. doi: 10.2500/aap.2021.42.210022

41. Becker RC. Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series. J Thromb Thrombolysis. 2021;52(3):692-707. doi: 10.1007/s11239-021-02549-6

42. Adegeest CY, van Gent JAN, Stolwijk-Swüste JM, et al. Influence of severity and level of injury on the occurrence of complications during the subacute and chronic stage of traumatic spinal cord injury: a systematic review. J Neurosurg Spine. 2021;1:1-21. doi: 10.3171/2021.7.SPINE21537

43. Eldahen KC, Rabchevsky AG. Autonomic dysreflexia after spinal cord injury: systemic pathophysiology and methods of management. Auton Neurosci. 2018;209:59-70. doi: 10.1016/j.autneu.2017.05.002

44. Cowan H, Lakra C, Desai M. Autonomic dysreflexia in spinal cord injury. BMJ. 2020;371:m3596. doi: 10.1136/bmj.m3596

45. Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open. 2021;11(10):e052777. doi: 10.1136/bmjopen-2021-052777

46. Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with postacute sequelae of COVID-19. Diabetes Obes Metab. 2021;23(9):2183-2188. doi: 10.1111/dom.14454

47. Costa J, Moreira A, Moreira P, Delgado L, Silva D. Effects of weight changes in the autonomic nervous system: a systematic review and meta-analysis. Clin Nutr. 2019;38(1):110-126. doi: 10.1016/j.clinu.2018.01.006

48. Quarti-Trevano F, Biffi A, Bonzani M, et al. Neuroadrenergic activation in obstructive sleep apnea syndrome: a systematic review
82. Zha K, Brook J, McLaughlin A, Blitshteyn S. Gluten-free diet in postural orthostatic tachycardia syndrome (POTS). *Chronic Illn.* 2022;17:423953221076984. doi: 10.1177/17423953221076984

83. Holdoway A. Addressing nutrition in the road map of recovery for those with long COVID-19. *Br J Community Nurs.* 2021;26(5):218-222. doi: 10.12968/bjcn.2021.26.5.218

84. Filippo LD, Lorenzo RD, D’Amico M, et al. COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: a post-hoc analysis of a prospective cohort study. *Clin Nutr.* 2021;40(4):2420-2426. doi: 10.1016/j.clinu.2020.10.043

85. Mills PB, Fung CK, Travlos A, Krassioukov A. Nonpharmacologic Management of Orthostatic Hypotension: a systematic review. *Arch Phys Med Rehabil.* 2015;96(2):366-375.e6. doi: 10.1016/j.apmr.2014.09.028

86. Ganesh R, Bonnes SLR, DiBaise JK. Postural tachycardia syndrome: nutrition implications. *Nutr Clin Pract.* 2020;35(5):818-825. doi: 10.1002/ncc.10564

87. van Dijk N, Quartieri F, Blanc JJ, et al. PC-trial investigators. Treatment of postural orthostatic tachycardia syndrome: a randomised controlled trial of counterpressure manoeuvres trial (PC-trial). *J Am Coll Cardiol.* 2006;48(6):1652-1657. doi: 10.1016/j.jacc.2006.06.059

88. Raj SR, Guzman JC, Harvey P, et al. Canadian cardiovascular society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. *Can J Cardiol.* 2020;36(3):357-372. doi: 10.1016/j.cjca.2019.12.024

89. Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. *Auton Neurosci.* 2018;215:28-36. doi: 10.1016/j.autneu.2018.04.008

90. Schlofeid JR, Chemali KR. Intravenous immunoglobulin therapy in refractory autoimmune Dysautonomias: a retrospective analysis of 38 patients. *Am J Ther.* 2019;26(5):e570-e582. doi: 10.1097/MTJ.0000000000000778

91. Deng J, Li H, Guo Y, et al. Transcutaneous vagus nerve stimulation attenuates autonomic-mediated cardiopulmonary dysfunction and inflammation in a rabbit model of postural tachycardia syndrome. *J Inter Card Electrophysiol.* 2022. doi: 10.1007/s10840-022-01144-w

92. Azabou E, Bao G, Bounab R, Heming N, Annane D. Vagus nerve stimulation: a potential adjunct therapy for COVID-19. *Front Med.* 2021;8:625836. doi: 10.3389/fmed.2021.625836

93. Soin A, Soin Y, Dann T, et al. Low-dose naltrexone use for patients with chronic regional pain syndrome: a systematic literature review. *Pain Physician.* 2021;24(4):E393-E406.

94. Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradiskin S. Potential therapeutic benefit of Low dose naltrexone in Myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential Melastatin 3 ion channels in pathophysiology and treatment. *Front Immunol.* 2021;12:687806. doi: 10.3389/fimmu.2021.687806

95. Ruzieh M, Grubb BP. Overview of the management of postural tachycardia syndrome in pregnant patients. *Auton Neurosci.* 2018;215:102-105. doi: 10.1016/j.autneu.2018.02.002

96. Blitshteyn S, Poya H, Bett GC. Pregnancy in postural tachycardia syndrome: clinical course and maternal and fetal outcomes. *J Matern Fetal Neonatal Med.* 2012;25(9):1631-1634. doi: 10.3109/14767058.2011.648671

97. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. *Cochrane Database Syst Rev.* 2017;2017(4):CD003200. doi: 10.1002/14651858.CD003200.pub7

98. Gibbons CH, Silva G, Freeman R. Cardiovascular exercise as a treatment of postural orthostatic tachycardia syndrome: a pragmatic treatment trial. *Heart Rhythm.* 2021;18(8):1361-1368. doi: 10.1016/j.hrthm.2021.01.017

99. Powell P, Bentall RP, Nye FJ, Edwards RHT. Randomised controlled trial of patient education to encourage graded exercise in chronic fatigue syndrome. *BMJ.* 2001;322(7283):387-390.

100. Bidonde J, Busch AJ, Schachter CL, et al. Aerobic exercise training for adults with fibromyalgia. *Cochrane Database Syst Rev.* 2017;6:CD012700. doi: 10.1002/14651858.CD012700

101. Tabaco LF, Tosto-Mancuso J, Wood J, et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life and participation. *Am J Phys Med Rehabil.* 2021;27:48-52. doi: 10.1097/PHM.0000000000001910

102. Putrino D, Tabaco LF, Tosto-Mancuso J, et al. Autonomic conditioning therapy reduces fatigue and improves global impression of change in individuals with Post-acute COVID-19 syndrome. 2021. doi: 10.21203/rs.3.rs-44099/v1

103. Brown A, Jason LA. Meta-analysis investigating post-exertional malaise between patients and controls. *J Health Psychol.* 2020;25(13-14):2053-2071. doi: 10.1177/135910531878416

104. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: international consensus criteria. *J Intern Med.* 2011;270(4):327-338. doi: 10.1111/j.1365-2796.2011.02428.x

105. Jordan J, Shannon JR, Diedrich A, et al. Interaction of carbon dioxide and sympathetic nervous system activity in the regulation of cerebral perfusion in humans. *Hypertension.* 2000;36(3):383-388. doi: 10.1161/01.hyp.36.3.383

106. Stewart JM, Pianosi P, Shaban MA, et al. Postural hyperventilation as a cause of postural tachycardia syndrome: increased systemic vascular resistance and decreased cardiac output when upright in all postural tachycardia syndrome variants. *J Am Heart Assoc Cardiovasc Cerebrovasc Dis.* 2018;7(13):e008854. doi: 10.1161/JAHA.118.008854

107. Stewart JM, Pianosi P, Shaban MA, et al. Hemodynamic characteristics of postural hyperventilation: POTS with hyperventilation versus panic versus voluntary hyperventilation. *J Appl Physiol.* 2018;125(5):1396-1403. doi: 10.1152/japplphysiol.00377.2018

108. Wood J, Tabaco LF, Tosto-Mancuso J, McCarthy D, Kontorovich A, Putrino D. Levels of end-tidal carbon dioxide are low despite normal respiratory rate in individuals with long COVID. *J Breath Res.* 2021;16(1):017101.

109. Jerath R, Edry JW, Barnes VA, Jerath V. Physiology of long pranayam breathing: neural respiratory elements may provide a mechanism that explains how slow deep breathing shifts the autonomic nervous system. *Med Hypotheses.* 2006;63(3):566-571. doi: 10.1016/j.mehy.2006.02.042

110. Physiotherapy W. *World Physiotherapy Response to COVID-19 Briefing Paper 9. Safe Rehabilitation Approaches for People Living with Long COVID: Physical Activity and Exercise.* London, UK; 2021.

111. Stewart JM, Warsy IA, Visintainer P, Terilli C, Medow MS. Supine parasympathetic withdrawal and upright sympathetic activation Underly abnormalities of the Baroreflex in postural tachycardia syndrome. *Hypertension.* 2021;77(4):1234-1244. doi: 10.1161/HYPERTENSIONAHA.120.16113

112. Leddy JJ, Kozlowski K, Donnelly JP, Pendergast DR, Epstein LH, Willer B. A preliminary study of subsymptom threshold exercise training for refractory Post- concussion syndrome. *Clin J Sport Med.* 2010;20(1):21-27. doi: 10.1097/JSM.0b013e31816dc22c

113. U.S. Department of Health Human Services Office for Civil Rights and U.S. Department of Justice Human Services Civil Rights Division Disability Rights Section. Guidance on “Long
COVID* as a Disability Under the ADA, Section 504, and Section 1557; 2021; Washington, D.C. accessed via https://www.hhs.gov/civil-rights/for-providers/civil-rights-covid19/guidance-long-covid-disability/index.html#footnote3_23fxl3

116. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021;22:43-55. doi:10.1016/S1473-3099(21)00480-6

117. Bergwerk M, Gonen T, Lustig Y. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474-1484.

118. Tran VT, Perrodeau E, Saldanha J et al. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France. SSRN. 2021;10.2139/ssrn.3932953

119. Strain WD, Sherwood O, Amitava B, Van der Togt V et al. The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID. Available at SSRN: https://ssrn.com/abstract=3868856 or 10.2139/ssrn.3868856

120. Massey D, Berrent D, Akrami A, et al. Change in symptoms and immune response in people with Post-acute sequelae of SARS-Cov-2 infection (PASC) after SARS-Cov-2 vaccination. medRxiv. doi:10.1101/2021.07.21.21260391

121. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Changes in the trajectory of long Covid symptoms following COVID-19 vaccination: community-based cohort study. medRxiv. doi:10.1101/2021.12.09.21267516

122. Taequet M, Dereon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022; 103:154-162. doi:10.1016/j.bbi.2022.04.013

123. Letter to President Biden and Congress; https://www.aapmr.org/docs/default-source/news-and-publications/covid/long-covid-post-final.pdf, Accessed 8/13/2021.

124. Centers for Disease Control and Prevention. Health Equity. https://www.cdc.gov/chronicdisease/healthequity/index.htm, Accessed 8/13/2021

125. The White House. Presidential Action: Executive Order On Advancing Racial Equity and Support for Underserved Communities Through the Federal Government. https://www.whitehouse.gov/briefing-room/presidential-actions/2021/01/20/executive-order-advancing-racial-equity-and-support-for-underserved-communities-through-the-federal-government/, Accessed 8/13/2021

126. AAPM&R. Principles of Inclusion and Engagement; https://www.aapmr.org/about-aapm-r/advancing-diversity-and-inclusion/principles-of-inclusion-and-engagement, Accessed 8/13/2021

APPENDIX 1: Sample symptom reporting table

| Blood Pressure (BP) | Systolic  | Diastolic | Pulse | Symptoms |
|---------------------|-----------|-----------|-------|----------|
| Supine              |           |           |       |          |
| Standing 3 min      |           |           |       |          |
| Standing 5 min      |           |           |       |          |
| Standing 7 min      |           |           |       |          |
| Standing 10 min     |           |           |       |          |